Zentiva Expands Eastwards

Czech drugmaker Zentiva recorded a disappointing performance on its home market in H107 with sales receding 5.6% to CZK2,226mn (US$115.08mn). Chief Financial Officer Petr Sulc blames recent drug market reforms, which have impacted volume sales.

To read the full article, please choose one of the following options: